Rise and shine, everyone. The middle of the week is upon us. Have heart, though. You made it this far, so why not hang on for another couple of days, yes? And what better way to make the time fly than to keep busy. So grab that cup of stimulation — our flavor today is chocolate raspberry — and get started. To help you along, we have assembled another menu of tidbits for you to peruse. Meanwhile, do keep us in mind if you hear anything interesting. We continue to accept — at absolutely no charge to you — postcards and telegrams. And of course, we hope you have a smashing day. …
As the gold rush over weight-loss drugs accelerates, Eli Lilly filed lawsuits against several compounding pharmacies, spas and wellness centers around the U.S. for selling unapproved versions of its Mounjaro diabetes drug, which is frequently used for combating obesity, STAT writes. The drug company accused four compound pharmacies of violating state laws because those versions were not approved by the U.S. Food and Drug Administration. In other lawsuits, Lilly accused several medical spas and wellness centers of trademark violations, false advertising, and unfair competition by selling drugs under the Mounjaro name.
The FDA declined to approve an application from ARS Pharmaceuticals for its lead product, which would become the first needle-free epinephrine product to treat severe allergic reactions, Pharmaphorum notes. The nasal spray, dubbed neffy, has been filed for use in adults and some children as an alternative to epinephrine injections such as EpiPen – which dominates the market for emergency medications for anaphylaxis – or its generic equivalents. ARS Pharma said it was “very surprised” by the complete response letter, since an FDA advisory committee recommended approval of the drug in May without any additional trials by a vote of 16 to 6.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect